Lemborexant for the Treatment of Insomnia: Direct and Indirect Comparisons With Other Hypnotics Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed

Conclusions: In Phase 3 trials, the benefit-risk ratio for lemborexant is favorable as measured by NNT, NNH, and LHH.Trial Registration: ClinicalTrials.gov identifiers: NCT02783729, NCT02952820.PMID:34077032 | DOI:10.4088/JCP.20m13795

Source: Journal of Clinical Psychiatry - June 2, 2021 Category: Psychiatry Authors: Leslie Citrome Timothy Juday Feride Frech Norman Atkins Source Type: research